Pas    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica4

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03723434
(ClinicalTrials.gov)
May 31, 201722/10/2018Physiology of Interregional Connectivity in the Human BrainPhysiology of Interregional Connectivity in the Human BrainHealthy;Stroke;Traumatic Brain Injury;Multiple SclerosisDevice: Single-pulse transcranial magnetic stimulation (spTMS);Device: Paired associative stimulation (PAS);Device: Repetitive transcranial magnetic stimulation (rTMS)Shirley Ryan AbilityLabNorthwestern UniversityUnknown status18 Years85 YearsAll76N/AUnited States
2NCT01453868
(ClinicalTrials.gov)
October 201113/10/2011The Effects of Aerobics Training on Balance in Patients With Multiple SclerosisThe Effects of Neuromuscular Training on Balance in Patients With Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingOther: Non Impact Aerobics;Other: Passive : lecture seriesNelson Mandela Metropolitan UniversityNULLRecruiting20 Years60 YearsBoth60Phase 0United States
3NCT00461396
(ClinicalTrials.gov)
May 200717/4/2007Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With BetaseronOpen-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 MonthsMultiple Sclerosis;Multiple Sclerosis, Relapsing-RemittingDrug: Interferon-1beta (Betaseron, BAY86-5046)BayerNULLCompleted18 Years50 YearsBoth104Phase 4United States
4EUCTR2006-000606-23-ES
(EUCTR)
23/11/200615/03/2012?Post-authorization safety study to check the potential association between the safetyprofile of beta interferon 1a and the body mass index or pharmacodynamics during thetitration phasePost-authorization safety study to check the potential association between the safetyprofile of beta interferon 1a and the body mass index or pharmacodynamics during thetitration phase - PASS-PD del escalado de dosis de Rebif Not applicalbe
MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Rebif 22 y 44 mcg
Product Name: Interferon-beta-1a
Other descriptive name: INTERFERON BETA-1A
Merck, S.L.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase -Spain